Regulatory flexibility can make continuous improvement possible.
Mark Rosolowsky
Advertisement
Mark Rosolowsky is the executive director of global regulatory sciencesâCMC at Bristol Myers Squibb
Articles by Mark Rosolowsky
Second in a three-part series that discusses the complexities of QbD implementation in biotech development.
First in a three-part series that discusses the complexities of QbD implementation in biotech product development.
Advertisement
Latest Updated Articles
Quality by Design for Biotechnology Products—Part 3Published: January 1st 2010 | Updated:
Quality by Design for Biotechnology Products—Part 2Published: December 1st 2009 | Updated:
Quality by Design for Biotechnology Products—Part 1Published: November 1st 2009 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
RNAnalytics CPHI Interview, Part Two: Nanoparticle Case Studies and Response to US mRNA Pullback
2
How Enzymatic Platforms May Change the Therapeutic RNA Supply Chain
3
How Is AI Transforming Biomanufacturing and Biopharma Workforce Training?
4
Achieving Real Impact Navigating the Data and Regulatory Barriers to AI Adoption in Bio/pharma
5
